Search global stocks & ETFs...Ctrl K
Learn Mode
MEDP
Stock Profile
07-22
Recommended Metric
Score Card
Explore Scores Tab
3.79
Good
Valuation Score
Key Score
4.00
Good
Management
4.00
Good
Growth
4.00
Good
Profitability
3.00
Average
Fin. Health
5.00
Very Good
Dividends
--
--
Analyst
1.00
Very Bad
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$565.09
Baseline
High
$519.75
▼
-8.02%
Avg
$449.46
▼
-20.46%
Low
$341.82
▼
-39.51%
Analyst Ratings based on 20 Analysts
Strong Buy
420%
Buy
525%
Hold
1050%
Sell
105%
Strong Sell
000%
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company is headquartered in Cincinnati, Ohio and currently employs 6,300 full-time employees. The company went IPO on 2016-08-11. The firm partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The firm also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.Read More